Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,425,500 papers from all fields of science
Search
Sign In
Create Free Account
teplizumab
Known as:
Immunoglobulin G1, Anti-(Human CD3 (Antigen)Epsilon-Chain)(Human-Mouse Monoclonal MGA031 Heavy Chain), Disulfide with Human-Mouse Monoclonal MGA031 Light-Chain Dimer
, hOKT3gamma1(Ala-Ala)
, humanized OKT3 gamma1(Ala-Ala)
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Antibodies, Monoclonal, Humanized
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Teplizumab in Relatives at Risk for Type 1 Diabetes.
O. Korsgren
,
Oskar Skog
,
J. Ludvigsson
New England Journal of Medicine
2019
Corpus ID: 207937471
2019
2019
Anti-CD3 drug keeps diabetes at bay
E. Dolgin
Nature Biotechnology
2019
Corpus ID: 202849713
No drug has ever delayed islet cell destruction. Now that teplizumab has, the challenge turns to identifying eligible recipients…
Expand
2019
2019
Preventing Type 1 Diabetes with Teplizumab
F. Stapleton
2019
Corpus ID: 198252675
Because type 1 diabetes mellitus (DM) is the result of immune destruction of pancreatic islet cells, immunologic interventions…
Expand
2019
2019
Teplizumab delays onset of type 1 diabetes mellitus
Alan Morris
Nature Reviews Endocrinology
2019
Corpus ID: 195657142
2019
2019
Evaluation einer Therapie mit dem Anti-CD3-Antikörper Teplizumab bei Verwandten von Typ-1-Diabetikern mit erhöhtem Erkrankungsrisiko
Isabel N. Schellinger
Der Diabetologe
2019
Corpus ID: 202641380
Hintergrund. Der Typ-1-Diabetes ist eine chronische Autoimmunerkrankung, die zur Zerstörung von…
Expand
2019
2019
Treatment Delays Onset of Diabetes in At-Risk Populations
Linda Peckel
2019
Corpus ID: 228711840
A single course of treatment with teplizumab delayed the development of type 1 diabetes in at-risk teens and children, shows a…
Expand
Review
2018
Review
2018
Immune Intervention for Type 1 Diabetes.
Bimota Nambam
,
N. Bratina
,
D. Schatz
Diabetes Technology & Therapeutics
2018
Corpus ID: 3316980
2013
2013
The Compelling Case for Anti-CD3 in Type 1 Diabetes
J. Skyler
Diabetes
2013
Corpus ID: 28060837
Immunotherapy trials in recent-onset type 1 diabetes (T1D) have had mixed results, with some therapies—anti-CD3 monoclonal…
Expand
2011
2011
More than insulin
M. Eisenstein
Nature Biotechnology
2011
Corpus ID: 2823566
For a century, insulin has been the only drug available to type 1 diabetics. Now a raft of novel drugs are coming through the…
Expand
Review
2011
Review
2011
Expert Review of Vaccines 10-year anniversary issue
A. Pollard
,
Lauren Constable
2011
Corpus ID: 73077187
From its launch in 2002, Expert Review of Vaccines has provided a unique forum for discussion and review of vaccine-related…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE